Rx Product News (April 2017)

APRIL 20, 2017




SILIQ

MARKETED BY: Valeant Pharmaceuticals International
INDICATION: The FDA has approved Siliq (brodalumab) injection for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond, or have lost response, to other systemic therapies.
DOSAGE FORM: Subcutaneous injection: 210 mg
FOR MORE INFORMATION: valeant.com



SPIRIVA RESPIMAT MARKETED BY: Boehringer Ingelheim
INDICATION: The FDA has expanded the indicated for the approved Spiriva Respimat (tiotropium bromide) for the long-term, once-daily maintenance treatment of asthma in individuals 6 years and older.
DOSAGE FORM: Oral inhalation: 1.25 mcg
FOR MORE INFORMATION: spiriva.com



PARSABIV MARKETED BY: Amgen
INDICATION: The FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on hemodialysis.
DOSAGE FORM: Injection: 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL
FOR MORE INFORMATION: amgen.com



TRULICITY
MARKETED BY: Eli Lilly
INDICATION: The FDA approved Eli Lilly’s updated label for its type 2 diabetes drug, Trulicity (dulaglutide), to include use in combination with basal insulin for adults with type 2 diabetes. The FDA included the changes to the approved product labeling to reflect this important information for prescribers.
DOSAGE FORM: Injection: 0.75 and 1.5 mg
FOR MORE INFORMATION: trulicity.com

SHARE THIS SHARE THIS
0

Treatment of Melanoma 

In this Pharmacy Times program for Health Systems Pharmacists, Nanaz Amini, PharmD, RPh, MS, of the Angles Clinic, provides a pharmacist’s perspective on the management of melanoma.  


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.